GILEAD SCIENCES INC CEDEAR EACH 4 REP 1 COM USD0.001GILEAD SCIENCES INC CEDEAR EACH 4 REP 1 COM USD0.001GILEAD SCIENCES INC CEDEAR EACH 4 REP 1 COM USD0.001

GILEAD SCIENCES INC CEDEAR EACH 4 REP 1 COM USD0.001

No trades
See on Supercharts

Key stats

Market capitalization
‪81.69 B‬USD
Dividend yield (indicated)
Price to earnings Ratio (TTM)
Basic EPS (TTM)
Net income (FY)
Revenue (FY)
Shares float
Beta (1Y)
0.53

About Gilead Sciences, Inc.

CEO
Daniel P. O'Day
Website
Headquarters
Foster City
Founded
1987
ISIN
ARBCOM4601C4
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.